Virios Therapeutics (VIRI) Competitors $5.88 -0.15 (-2.49%) As of 02/20/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends VIRI vs. PROK, ABVX, ORGO, CMPX, AKBA, PRTC, ALT, CDXC, KMDA, and MREOShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include ProKidney (PROK), ABIVAX Société Anonyme (ABVX), Organogenesis (ORGO), Compass Therapeutics (CMPX), Akebia Therapeutics (AKBA), PureTech Health (PRTC), Altimmune (ALT), ChromaDex (CDXC), Kamada (KMDA), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. ProKidney ABIVAX Société Anonyme Organogenesis Compass Therapeutics Akebia Therapeutics PureTech Health Altimmune ChromaDex Kamada Mereo BioPharma Group ProKidney (NASDAQ:PROK) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations. Do analysts prefer PROK or VIRI? ProKidney presently has a consensus price target of $4.50, indicating a potential upside of 200.00%. Virios Therapeutics has a consensus price target of $3.00, indicating a potential downside of 48.98%. Given ProKidney's higher possible upside, equities research analysts clearly believe ProKidney is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer PROK or VIRI? In the previous week, ProKidney's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score. Company Overall Sentiment ProKidney Neutral Virios Therapeutics Neutral Does the MarketBeat Community believe in PROK or VIRI? ProKidney received 5 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 57.14% of users gave ProKidney an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% Virios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Is PROK or VIRI more profitable? ProKidney's return on equity of 0.00% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% Virios Therapeutics N/A -130.33%-115.00% Do insiders & institutionals have more ownership in PROK or VIRI? 51.6% of ProKidney shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 41.5% of ProKidney shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, PROK or VIRI? Virios Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidneyN/AN/A-$35.47M-$0.55-2.73Virios TherapeuticsN/AN/A-$5.30M-$0.27-21.78 Which has more volatility & risk, PROK or VIRI? ProKidney has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. SummaryProKidney beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$113.24M$7.04B$5.77B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-21.786.1326.4618.81Price / SalesN/A314.26449.1576.64Price / CashN/A67.8344.0437.47Price / Book29.406.747.634.64Net Income-$5.30M$138.11M$3.18B$245.69M7 Day Performance-12.37%-2.02%-1.82%-2.63%1 Month Performance214.44%-1.54%0.22%-2.37%1 Year Performance1,411.57%-3.14%17.49%13.65% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$5.88-2.5%$3.00-49.0%+1,411.6%$113.24MN/A-21.785Gap DownPROKProKidney1.3357 of 5 stars$1.61+0.6%$4.50+179.5%-1.3%$469.57MN/A-2.933Gap UpABVXABIVAX Société Anonyme2.0141 of 5 stars$7.40+3.2%$38.67+422.5%-33.4%$468.94MN/A0.0061News CoverageORGOOrganogenesis3.9608 of 5 stars$3.70+0.5%$5.00+35.1%-6.4%$465.20M$433.14M-61.67950News CoverageCMPXCompass Therapeutics3.3128 of 5 stars$3.38-2.0%$11.17+230.4%+62.2%$465.05M$850,000.00-9.1320Analyst ForecastAKBAAkebia Therapeutics3.971 of 5 stars$2.13-0.5%$7.50+252.1%+26.8%$464.72M$194.62M-9.26430Analyst DowngradePositive NewsPRTCPureTech Health2.1556 of 5 stars$18.95flat$45.00+137.5%-20.7%$453.66M$3.33M0.00100ALTAltimmune2.6074 of 5 stars$6.37+2.2%$20.83+227.1%-21.8%$453.03M$430,000.00-4.1150Short Interest ↓News CoveragePositive NewsCDXCChromaDex4.4644 of 5 stars$5.87+5.2%$8.00+36.3%+256.6%$448.35M$83.57M587.59120News CoverageKMDAKamada4.0332 of 5 stars$7.78-2.1%$14.50+86.4%+24.1%$447.19M$142.52M27.79360High Trading VolumeMREOMereo BioPharma Group3.0511 of 5 stars$2.87-0.3%$7.83+172.9%-19.4%$445.28M$10M0.0040 Related Companies and Tools Related Companies ProKidney Alternatives ABIVAX Société Anonyme Alternatives Organogenesis Alternatives Compass Therapeutics Alternatives Akebia Therapeutics Alternatives PureTech Health Alternatives Altimmune Alternatives ChromaDex Alternatives Kamada Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts